University of Oulu: Butterfly Wings As Inspiration for More Effective Solar Panels
30.6.2020 07:05:00 EEST | Business Wire | Press release
The color of butterflies is mainly attributed to structural color as a result of diffraction of natural light. However, black color denotes trapping of sunlight within the butterfly scales. In some extreme cases, a butterfly will be rapidly de-iced through light-heat conversion within black scales on wings. Inspired by such a natural light harvesting process, scientists in the University of Oulu, Finland, research unit NANOMO carefully examined nanostructures of black scales obtained from different butterflies and assessed their light trapping abilities when placed on Si-based solar panels.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200629005043/en/
New study: Very effective nanostructures biomimicked from black scales of butterflies can be used for antireflective coating on solar panels.Photo: University of Oulu
Even with apparently the same dark color, butterfly scales have varied nanostructures depending on their species. For example, the morphology of Ornithoptera priamus scale consists of parallel V-shaped gullies formed between two ridges and connected by thin layers. This is very different from the scale structure of other three species, Tirumala limniace, Graphium doson, and Papilio protenor cramer, where the structures consist of round ridges spaced by arrays of 1, 2, and 3 holes. Correspondingly, light reflection on the black scales differs, with the one on the black part of Ornithoptera priamus owing minimum values ranging from 1-5% at the visible light region.
Using these structures as antireflective patterns will help sunlight harvesting on Si based photovoltaics. Computer simulated results showed that after placing these nanostructures on Si solar panels, surface backscattering decreased substantially. The scale structure of Ornithoptera priamus gave the best antireflection. Light reflection decreased from more than 35% on bare Si panel down to less than 5%. As a result, the short-circuit current, i.e. the largest current that can be obtained from the photovoltaic cell, was increased by 66%. Experimental realizations of such a strategy have also been proposed.
The latest research progress continues the world-leading role of NANOMO group in biomimicry. The unit pioneers in applying fundamental concepts in physics to applied photonics and solar energy harvesting. The research was coordinated by Professors Wei Cao and Marko Huttula, University of Oulu.
Considering the large volume of Si solar panels in use, it is foreseen that the butterfly wings can provide a major contribution to clean energy production.
Article:
Zhongjia Huang, Xinying Shi, Gang Wang, Petri Leukkunen, Marko Huttula, Wei Cao:
Antireflective design of Si-based photovoltaics via biomimicking structures on black butterfly scales, Solar Energy, Volume 4. DOI: https://doi.org/10.1016/j.solener.2020.05.031
sciencedirect.com 2020
https://www.sciencedirect.com/science/article/pii/S0038092X2030520X
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200629005043/en/
Contact information
More information:
Associate Professor Wei Cao
University of Oulu
NANOMO Research Unit
tel. +358 400 897 982
e-mail: Wei.Cao@oulu.fi
Professor Marko Huttula
University of Oulu
NANOMO Research Unit
tel. +358 400 566 218
e-mail: Marko.Huttula@oulu.fi
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 08:00:00 EEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the
Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 05:00:00 EEST | Press release
Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated over the three years through 2028. The amount to be awarded to Helical Fusion will be announced following the formal grant
Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28 [1]1.9.2026 00:35:00 EEST | Press release
ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will synergistically blend ITCI’s AI-led capabilities across Cloud, Data Analytics, PLM, SAP, enterprise transformation, industry-spe
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 22:07:00 EEST | Press release
Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 22:00:00 EEST | Press release
BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional research, development, and manufacturing to deliver breakthrough cancer treatments worldwide.” Improved access to oncol
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
